{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:39:31Z","timestamp":1788399571658,"version":"build-2803163510"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2016,5,27]],"date-time":"2016-05-27T00:00:00Z","timestamp":1464307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81272701"],"award-info":[{"award-number":["81272701"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0156449","type":"journal-article","created":{"date-parts":[[2016,5,27]],"date-time":"2016-05-27T13:34:19Z","timestamp":1464356059000},"page":"e0156449","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Expression and Characterization of a Potent Long-Acting GLP-1 Receptor Agonist, GLP-1-IgG2\u03c3-Fc"],"prefix":"10.1371","volume":"11","author":[{"given":"Yi","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyou","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongru","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinling","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,5,27]]},"reference":[{"issue":"6","key":"ref1","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.clinthera.2012.04.013","article-title":"Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review","volume":"34","author":"VR Aroda","year":"2012","journal-title":"Clinical therapeutics"},{"issue":"9","key":"ref2","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1210\/me.2002-0084","article-title":"Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism","volume":"16","author":"PE Light","year":"2002","journal-title":"Molecular endocrinology (Baltimore, Md)"},{"issue":"17","key":"ref3","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1021\/jm100602m","article-title":"Development of potent glucagon-like peptide-1 agonists with high enzyme stability via introduction of multiple lactam bridges","volume":"53","author":"EN Murage","year":"2010","journal-title":"Journal of medicinal chemistry"},{"issue":"6","key":"ref4","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"LL Baggio","year":"2007","journal-title":"Gastroenterology"},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1900\/RDS.2008.5.73","article-title":"Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors","volume":"5","author":"RE Pratley","year":"2008","journal-title":"The review of diabetic studies: RDS"},{"issue":"6","key":"ref6","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"SE Inzucchi","year":"2012","journal-title":"Diabetes care"},{"issue":"2\u20133","key":"ref7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0167-0115(98)00155-4","article-title":"Biological activity of GLP-1-analogues with N-terminal modifications","volume":"79","author":"EG Siegel","year":"1999","journal-title":"Regulatory peptides"},{"issue":"5","key":"ref8","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/psc.942","article-title":"Preparation and characterization of a novel exendin-4 human serum albumin fusion protein expressed in Pichia pastoris","volume":"14","author":"YS Huang","year":"2008","journal-title":"Journal of peptide science: an official publication of the European Peptide Society"},{"issue":"14","key":"ref9","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1016\/j.bmcl.2013.05.022","article-title":"Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity","volume":"23","author":"M Lorenz","year":"2013","journal-title":"Bioorganic & medicinal chemistry letters"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.tibtech.2014.11.001","article-title":"Fc fusion as a platform technology: potential for modulating immunogenicity","volume":"33","author":"D Levin","year":"2015","journal-title":"Trends in biotechnology"},{"issue":"6","key":"ref11","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ijo.2011.158","article-title":"Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide","volume":"36","author":"A Astrup","year":"2012","journal-title":"International journal of obesity (2005)"},{"key":"ref12","first-page":"29","article-title":"Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials","volume":"5","author":"L Macconell","year":"2012","journal-title":"Diabetes, metabolic syndrome and obesity: targets and therapy"},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1111\/j.1742-1241.2010.02465.x","article-title":"The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes","volume":"64","author":"D Russell-Jones","year":"2010","journal-title":"International journal of clinical practice"},{"issue":"6","key":"ref14","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1210\/jc.2010-2822","article-title":"Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials","volume":"96","author":"JB Buse","year":"2011","journal-title":"The Journal of clinical endocrinology and metabolism"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ymeth.2013.06.035","article-title":"An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations","volume":"65","author":"O Vafa","year":"2014","journal-title":"Methods (San Diego, Calif)"},{"issue":"11","key":"ref16","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/jps.20178","article-title":"Antibody pharmacokinetics and pharmacodynamics","volume":"93","author":"ED Lobo","year":"2004","journal-title":"Journal of pharmaceutical sciences"},{"issue":"1\u20133","key":"ref17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.regpep.2011.05.002","article-title":"The N-terminal alanine-extended GLP-1\/IgG-Fc fusion protein confers resistance to DPP-IV and reduces serum glucose level in db\/db mice","volume":"170","author":"HS Chung","year":"2011","journal-title":"Regulatory peptides"},{"issue":"7","key":"ref18","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1007\/s001250051238","article-title":"Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells","volume":"42","author":"J Buteau","year":"1999","journal-title":"Diabetologia"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jconrel.2013.07.021","article-title":"A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection","volume":"172","author":"M Amiram","year":"2013","journal-title":"Journal of controlled release: official journal of the Controlled Release Society"},{"issue":"8","key":"ref20","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1248\/bpb.23.941","article-title":"Expression and characterization of human rheumatoid factor single-chain Fv","volume":"23","author":"Y Hashimoto","year":"2000","journal-title":"Biological & pharmaceutical bulletin"},{"issue":"4","key":"ref21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/dmrr.1080","article-title":"Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein","volume":"26","author":"W Glaesner","year":"2010","journal-title":"Diabetes\/metabolism research and reviews"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/biot.201300305","article-title":"Pichia pastoris secretes recombinant proteins less efficiently than Chinese hamster ovary cells but allows higher space-time yields for less complex proteins","volume":"9","author":"A Maccani","year":"2014","journal-title":"Biotechnology journal"},{"issue":"Suppl 3","key":"ref23","doi-asserted-by":"crossref","first-page":"S434","DOI":"10.2337\/diabetes.51.2007.S434","article-title":"The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion","volume":"51","author":"PE MacDonald","year":"2002","journal-title":"Diabetes"},{"issue":"12","key":"ref24","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"JJ Meier","year":"2012","journal-title":"Nature reviews Endocrinology"},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jep.2009.09.055","article-title":"Astragalus polysaccharide improves insulin sensitivity in KKAy mice: regulation of PKB\/GLUT4 signaling in skeletal muscle","volume":"127","author":"M Liu","year":"2010","journal-title":"Journal of ethnopharmacology"},{"issue":"12","key":"ref26","doi-asserted-by":"crossref","first-page":"e83509","DOI":"10.1371\/journal.pone.0083509","article-title":"A tripeptide Diapin effectively lowers blood glucose levels in male type 2 diabetes mice by increasing blood levels of insulin and GLP-1","volume":"8","author":"J Zhang","year":"2013","journal-title":"PloS one"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.peptides.2013.01.010","article-title":"Long-term treatment with EXf, a peptide analog of Exendin-4, improves beta-cell function and survival in diabetic KKAy mice","volume":"40","author":"GJ Hou","year":"2013","journal-title":"Peptides"},{"issue":"3","key":"ref28","first-page":"S12","article-title":"Neutralizing antibodies to multiple sclerosis treatments","volume":"10","author":"HS Rossman","year":"2004","journal-title":"Journal of managed care pharmacy: JMCP"},{"issue":"9645","key":"ref29","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","article-title":"Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study","volume":"372","author":"DJ Drucker","year":"2008","journal-title":"Lancet (London, England)"},{"issue":"10","key":"ref30","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","article-title":"Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial","volume":"52","author":"D Russell-Jones","year":"2009","journal-title":"Diabetologia"},{"issue":"7","key":"ref31","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc08-2124","article-title":"Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)","volume":"32","author":"B Zinman","year":"2009","journal-title":"Diabetes care"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1124\/pr.55.1.6","article-title":"International Union of Pharmacology. XXXV. The glucagon receptor family","volume":"55","author":"KE Mayo","year":"2003","journal-title":"Pharmacological reviews"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0156449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T11:35:09Z","timestamp":1540294509000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0156449"}},"subtitle":[],"editor":[{"given":"Christian","family":"Holscher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,5,27]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,5,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0156449","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,27]]}}}